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Introduction  Project aim 
Diabetis is a widespread disease and numbers of patients are supposed to 
rise to 380 million within the next 20 years. Therefore products, which are 
able to minimize secondary effects of diabetis, will be of demanding 
interest. As the blood sugar level in diabetic patients is increased, 
expanded occurance of advanced glycated end (AGE) products can be 
observed. These products are generated when sugars interact with lysine 
residues of amino acids in a non-enzymantic reaction and result in a 
crosslinking of proteins. In skin collagen I is the most prominent matrix 
protein. AGE formation in collagen structures result in a decreased matrix 
elasticity. 
 
 The aim of the project presented here was to 
establish and characterize a three 
dimensional skin model, which exhibits a 
glycated dermal compartment, similar to 
diabetic skin. 
Such a specialized model is intended to serve 
as a tool to study the cellular pathways of skin 
cell answers as well as the impact of potent 
drugs. 
   
Materials and Methods 
For collagen gylcation a collagen solution (5mg/ml in 0.02N acetic acid) was mixed with methylglyoxal (MGO), in order to obtain a 
final collagen concentration of 3mg/ml in acetic acid 0.5N enriched with MGO (final concentration: 250mM). The mixture was 
incubated for 64h at 22°C. After dialysis and measurement of AGE product formation (λem 440nm and λex 355nm) the solution 
was mixed with the same volume of non-glycated collagen solution and human primary fibroblasts (Provitro, Germany) to a final 
concentration of 1.2210
4
 cells/ml. The cellular hydrogels were incubated until contraction in DMEM/F12 medium. Human primary 
keratinocytes (Provitro, Germany) were seeded on top of the gels and cultivated submerged for 2 -4 days before exposing the cells 
to the air interface. Models were harvested after 10-11 days after the air-lift and analysed by histological and immunhistological 
methods.  
 
Results and Discussion 
 
Glycation of Collagen I was effective, 
as shown by increased fluorescence 
intensities (n=3) and delayed gel 
contraction (data not shown) by 
fibroblasts. As the underlying Maillard 
reaction is hardly controllable, a batch-
to batch variation occurred, resulting in 
different fluorescence intensities. 
Nevertheless, the glycated matrix was 
always polymerizable and feasible for 
organotypic skin model creation.  
 
 
As for non-glycyted collagen (A) 
all epidermal layers were 
established on a gylcated 
dermal matrix (B) and epidermal 
thickness was about the same 
size as on native collagen 
matrix. But there was a 
difference in epidermal layer 
morphology. Keratinocytes 
seemed to differentiate in lower 
epidermal layers when cultivated 
on a gylcated collagen matrix.  
 
 
Immunhistological analysis of vimentin 
(blue) and nuclei counterstain with 
propidium iodite (red) revealed an 
interesting phenomenom. The 
distribution of intermediary filaments of 
fibroblasts differd in glycated (B) 
collagen I hydrogels from the 
unglycated control (A). Fragmentation 
of vimentin was obviously increased. 
The fact, that vimentin plays a major 
role in AGE related skin alteration, was 
already shown in 2D fibrobalsts cell 
cultures by Kueper et al (Ann. N.Y. 
Acad. Sci., 2008). 
Conclusion 
In order to create organotypic skin models, which 
simulate the characteristics of aged or diabetic skin, the 
following conclusions can be drawn: 
 Glycation of collagen I by a non-enzymatic Maillard 
reaction is hardly controllable 
 Epidermal differentiation is altered on glycated 
dermal equivalent 
 Vimentin distribution is altered in glycated 3D 
dermal models 
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